SCHEMBL23510959

SCHEMBL23510959

CC(=O)c1c(O)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.58
GRIN3B O60391 2/20 0.58
GRIN1 Q05586 2/20 0.58
GRIN2A Q12879 2/20 0.58
GRIN2B Q13224 2/20 0.58
GRIN2C Q14957 2/20 0.58
GRIN3A Q8TCU5 2/20 0.58
KDM4E B2RXH2 1/20 0.56
GSK3B P49841 1/20 0.56
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 1/20 0.56
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
LMNA P02545 1/20 0.51
CSF1R P07333 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23498272 0.86 CSF1R (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30044896 0.86 CSF1R (0.49) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11375916 0.86 KDM4E (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25430492 0.85 SIRT1 (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31139832 0.85 SIRT1 (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6313673 0.84 GSK3B (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6519951 0.84 GSK3B (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6513986 0.82 GRIN2D (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6513990 0.82 GRIN2D (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6046700 0.82 SERPINE1 (0.47) KDM4EGSK3BMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230052747-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS TES PHARMA S.R.L. (IT) 2023-02-16 US disclosed
EP-4073054-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS Fondazione Istituto Italiano di Tecnologia (IT) 2022-10-19 EP disclosed
WO-2021116999-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230052747-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS RAD51, BRCA1, FANCI GRIN2D 4588/4885GRIN3B 3802/4885GRIN1 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.